Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.1.7 (acetylcholinesterase)
 28,390 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

BACKGROUND: The aim of the current study was to provide general practitioners with an overview of the available treatment options for Alzheimer's disease (AD). Since general practitioners provide the majority of medical care for AD patients, they should be well versed in treatment options that can improve function and slow the progression of symptoms. DESIGN: Biomedical literature related to acetylcholinesterase inhibitors (AChEIs) was surveyed. In the United States, there are four AChEIs approved for the treatment of AD: tacrine, donepezil, rivastigmine, and galantamine. There are other agents under investigation, but at present, AChEIs are the only approved drug category for AD treatment. MEASUREMENTS AND MAIN RESULTS: AD is becoming a major public health concern and underdiagnosis is a significant problem (with only about half of AD patients being diagnosed and only half of those diagnosed actually being treated). Clinical trials have demonstrated that patients with AD who do not receive active treatment decline at more rapid rates than those who do. CONCLUSIONS: Given that untreated AD patients show decline in three major areas (cognition, behavior, and functional ability), if drug treatment is able to improve performance, maintain baseline performance over the long term, or allow for a slower rate of decline in performance, each of these outcomes should be viewed a treatment success.
Ann Gen Hosp Psychiatry 2003 Jan 29
PMID:Current pharmacologic options for patients with Alzheimer's disease. 1260 26

Isolated frog sartorii were exposed for 30 minutes to HETP-an irreversible anti-cholinesterase, and were then soaked in Ringer's at 15 degrees C. for 16 hours. At the end of the period of soaking the mean resting potential of the muscle fibers was only 29 mv. The decrease in the resting potential of the HETP-treated muscles was accompanied by a loss of potassium and a gain in sodium by the muscles. The effect of anticholinesterases on sodium extrusion was studied by incubating the muscles in a Ringer's containing half of the normal amount of sodium. The muscles respond by extruding sodium against a concentration gradient into the external medium. Sodium extrusion was blocked by prior exposure of the muscle to HETP, and reversibly blocked by exposure to physostigmine. The inhibition of sodium extrusion by physostigmine was correlated with the inhibition of the intracellular cholinesterase. Sodium extrusion was also blocked by high concentrations of 2-methyl-1,4-napthaquinone 8-sulfonic acid and by alpha-ketoglutarate, which are known to inhibit choline acetylase in vitro. But sodium extrusion was not affected by a third inhibitor of choline acetylase, phenobarbital. Sodium extrusion was unaffected by KCN and partially blocked by IAA. The IAA block was eliminated by the addition of pyruvate. It is concluded that either glycolysis or oxidative metabolism can furnish the energy needed for sodium extrusion.
J Gen Physiol 1958 May 20
PMID:The effect of enzyme inhibitors on the resting potential and on the ion distribution of the sartorius muscle of the frog. 1352 72

Frog skin cholinesterase is largely of the serum (pseudocholinesterase) type. For whole skin, the activity at 10(-1) AcChCl is 4.9 microl./mg. N/hr. Tela subcutanea isolated by dissection exhibits an activity of 65 microl./mg. N/hr. at 10(-1) AcChCl. Since about one-tenth of the nitrogen of the skin is located in the tela subcutanea, it is estimated that more than 90 per cent of the enzyme is associated with this tissue layer.
J Gen Physiol 1958 Jul 20
PMID:The characterization and localization of frog skin cholinesterase. 1356 3

An enzymatic ion exchange model for active sodium transport is described. Kinetic equations relating net flux to time, and to concentration difference across the actively transporting membrane are derived. The second of these equations is tested, using the isolated frog skin in the "short-circuit" apparatus of Ussing. Reasonable linearity, as predicted by this equation, is observed. The passive permeability coefficient for Na(+), is calculated as 5.3 x 10(-4) +/- 5.3 x 10(-4) cm./hr. If cholinesterase is assumed to be the enzyme responsible for transport, the activity required to account for the observations reported here is 17.7 x 10(-4) mmoles/cm.(2)/hr.
J Gen Physiol 1959 Jan 20
PMID:An enzymatic ion exchange model for active sodium transport. 1362 Aug 92

DFP(32), used to label erythrocytes in vitro, combines with cell constituents in two stages, the first almost immediate and involving tributyrinase inactivation, the second slower (more than 40 minutes) involving cholinesterase inactivation. Raising the DFP concentration increases the amount irreversibly bound, but increases even more the immediate post-transfusion elution, and DFP is unsuited for investigating erythrocyte viability of stored samples. In vivo tagging by intramuscular injection is satisfactory and normal survival curves are linear since the sample tagged has normal age distribution of cells in absence of random destruction. Here DFP(32) curves are easier to interpret than Cr(51) curves. In sheep, chromium elution occurs at two different rates producing a rapid initial drop followed by a slower one of about 3 per cent daily. Random destruction alters cell age distribution. New equations are derived for cases in which this is constant both with and without chromium elution; they were applied satisfactorily to dog and sheep blood. Analysis of such curves is difficult; approximate values for random destruction rates can be obtained though not potential life spans. Chromium curves can be analyzed only with the help of DFP(32) or similar curves, and yield little additional information. DFP(32) and chromium can be used simultaneously to provide controls.
J Gen Physiol 1960 Mar
PMID:The use of DFP32 as a red cell tag with and without simultaneous tagging with chromium 51 in certain animals in the presence or absence of random destruction. 1381 76

An overview of studies on the issue of dementia in Parkinson's disease shows that, over time, there has been an evolution in the perception of the magnitude of the problem and of its nature. Dementia seems today to be part of the disease. This change in the understanding of the disease can be accounted for by various methodological problems and by difficulties, on one hand, in the definition of dementia and its differentiation from other conditions, and, on the other hand, in the diagnosis of the disease itself in individual cases. Optimal therapeutic strategies are also examined, either based on cholinesterase inhibitors or antiparkinsonian drugs and symptomatic measures.
Ann Gen Psychiatry 2006 Aug 08
PMID:Phenomenology and management of cognitive and behavioral disorders in Parkinson's disease. Rise and logic of dementia in Parkinson's disease. 1689 6

In vitro inhibition of bovine erythrocytes acetylcholinesterase (AchE) by separate and simultaneous exposure to organophosphorous insecticide malathion and the transformation products, which are generally formed during the storage or natural as well as photochemical degradation pathways of malathion, was investigated. The increasing concentration of malathion, its oxidation product - malaoxon and isomerisation product - isomalathion inhibited AChE activity in a concentration-dependent manner. The half-maximum inhibitory concentrations (IC(50) values): (3.2 +/- 0.1) x 10(-5) mol/l, (4.7 +/- 0.8) x 10(-7) mol/l and (6.0 +/- 0.5) x 10(-7)mol/l were obtained from the inhibition curves induced by malathion, malaoxon and isomalathion, respectively. However, the products formed due to photoinduced degradation, phosphorodithioic O,O,S-trimethyl phosphorodithioic ester (OOS(S)) and O,O-dimethyl thiophosphate did not noticeably affect the enzyme activity at all investigated concentrations, while diethyl maleate inhibited the AChE activity at concentrations >10 mmol/l. By simultaneous exposure of the enzyme to malaoxon and isomalathion in various concentration combinations the additive effect was achieved by low concentration of inhibitors, while the antagonistic effect was obtained at high concentration (>or= 3 x 10(-7) mol/l) of inhibitors. Inhibitory power of irradiated samples of 1 +/- 10(-5) mol/l malathion can be attributed to the formation of malaoxon and isomalathion, organophosphates about 100 times more toxic than their parent compound, while the presence of non-inhibiting degradation product OOS(S) did not affect the inhibitor efficiency of inhibiting malathion by-products, malaoxon and isomalathion.
Gen Physiol Biophys 2007 Dec
PMID:Inhibition of AChE by single and simultaneous exposure to malathion and its degradation products. 1828 41

A model of concentration changes across the synaptic cleft during a single quantum release is presented that can be used for description and characterization of the kinetic in postsynaptic current development under the influence of different antagonists, modulators, desensitization promoters or complex channel blockers. The model enables the calculation of the relative number of open channels as a function of time for two standard cases - when acetylcholinesterase (AChE) is either active or inhibited. One outcome of the present model is that the variable part of AChE activity is zero at the moment of acetylcholine (Ach) release and then increases. This is in contrast to common view that the activity of AChE at the initial moment of release of quanta is maximal and decreases over the time course of quantum action. However, the model explains why non-quantal ACh leakage from the nerve terminal creating a concentration of approximately 10(-8) mol.l(-1) in the cleft can escape hydrolysis by intrasynaptically located cholinesterase and reach the subsynaptic membrane. The model can also be used for theoretical considerations of time and amplitude changes during repetitive nerve-evoke quanta release.
Gen Physiol Biophys 2008 Mar
PMID:Model of concentration changes across the synaptic cleft during a single quantum release. 1843 79

Atropinesterase was found to exist in approximately one out of every four rabbits, and no relation could be observed between the incidence of the enzyme and season, sex, color, age, or weight. The occurrence of the enzyme was also shown to be unrelated to that of cholinesterase. The distribution of atropinesterase in the blood and organs of rabbits was studied; the animals devoid of the enzyme in their blood contained no demonstrable activity in any of the organ extracts tested. The presence of atropinesterase in frog liver, and its absence from the serum, has been confirmed. Hydrolysis of homatropine, but not atropine, by guinea pig liver was observed, while the serum was without action on either of the compounds. On this basis the possibility arises that guinea pig liver contains a homatropinesterase enzyme separate from atropinesterase. It was shown that lack of atropinesterase activity in certain rabbits is not likely to be due to the presence of a naturally occurring inhibitor. It has been demonstrated that contrary to previous indications neither fresh egg white nor yolk possess atropinesterase activity. The specificity of tropinesterases was investigated and evidence was presented for the possible existence of two distinct enzymes, cocainesterase and tropacocainesterase.
J Gen Physiol 1941 Nov 20
PMID:THE OCCURRENCE AND DISTRIBUTION OF ATROPINESTERASE, AND THE SPECIFICITY OF TROPINESTERASES. 1987 65

1. The kinetics of the reversible combination of one enzyme center with one molecule of a substrate or inhibitor is treated as a true bimolecular instead of a pseudomonomolecular reaction. The general equations describing such a reaction are presented and analyzed algebraically and graphically. 2. A new term, "specific concentration," is introduced to denote the concentration of reactants in units equal to the dissociation constant. Its use makes the kinetic equations universally applicable to all reversible systems of the given type. 3. It is shown that such a system exhibits three "zones" of behavior. Each zone is characterized and shown to exhibit significant differences in the function relating the concentrations of the components of the system at equilibrium. The zone boundaries are rigorously defined in terms of the specific enzyme concentration, for the mathematical error tolerable with a given experimental accuracy; and approximate boundaries for practical use are proposed. 4. The classical treatment of enzyme kinetics is shown to be a limiting case valid only for low specific enzyme concentrations (zone A) and to be inapplicable in a number of systems whose dissociation constants are very small or whose molar enzyme concentrations are very great, and in which, therefore, the specific enzyme concentrations are large. See Table I for a summary of zone differences. 5. In an enzyme system containing substrate or inhibitor, dilution before determination of reaction velocities is shown to be a crucial operation, entailing large changes in the fraction of enzyme in the form of a complex. The changes in fractional activity or inhibition with dilution are shown to be a function of specific enzyme concentration, the dilution factor, and the fraction of enzyme initially in the form of complex. Equations are given permitting the calculation of the state of the system at any concentration. The errors introduced into physiological work by failure to take the dilution effect into account are pointed out. 6. Experimental data are presented showing that the system composed of serum cholinesterase and physostigmine behaves as predicted by the dilution effect equations. 7. Two other conclusions of practical pharmacological importance are drawn from the theory of zone behavior: (a) The finding that a biological response is a linear function of the dose of a drug does not necessarily mean that the reaction is irreversible, but only that if reversible, the reactant with which the drug combines has a high specific concentration. (b) If a tissue enzyme has a high specific concentration, all reversible inhibitors will be equally potent in combining with it, regardless of their relative potency in dilute systems; provided only that their dissociation constants are within certain broad limits. 8. It is shown how the type of analysis here applied to bimolecular reactions can be applied in toto to systems of the type E + nX left harpoon over right harpoon EX(n), where n molecules of substrate or inhibitor unite with one enzyme center. The zone boundaries and the magnitude of the dilution effect change with n, but the general characteristics of the zones are the same for all values of n. 9. Since the analysis is based only on mass law assumptions, it is applicable to any system that is formally analogous to the one here treated.
J Gen Physiol 1943 Jul 20
PMID:ZONE BEHAVIOR OF ENZYMES : ILLUSTRATED BY THE EFFECT OF DISSOCIATION CONSTANT AND DILUTION ON THE SYSTEM CHOLINESTERASE-PHYSOSTIGMINE. 1987 67


<< Previous 1 2 3 4 5 6 7 8 9 Next >>